Year-end Sale % OFF 
Abstract
The present study was conducted to evaluate the adherence to standard treatment regimen in Bangabandhu Sheikh Mujib Medical University (BSMMU) for the treatment of corona virus disease 19 (COVID-19) patients. The study assessed the awareness of prescribers, adherence to treatment guidelines and reasons for non-adherence. A questionnaire survey was conducted followed by a retrospective and prospective medical review and in-depth interview. The study revealed that 79.9% of key prescribers are aware of treatment guidelines. Adherence was 28.4% in moderate cases and 53.3% in severe cases and difference was highly statistically significant (p<0.001). Adherence in moderate cases was highest in patients with hypertension (43.3%) and lowest in bronchial asthma (16.6%). Adherence in severe cases was highest with diabetes (80%) and lowest in bronchial asthma (20 %). In COVID-19 patients, the adherence was highest with International Guideline (96%), followed by institutional Guideline (74.6%) and National Guideline (23.5%). There is significant variation in extent of adherence in different age group of patients, co-morbidities and categories of guidelines. BSMMU J 2021; 14 (COVID -19 Supplement): 13-18
Highlights
This is an observational cross-sectional type of study, and the study was conducted among the COVID-19 patients who were admitted in COVID unit of Bangabandhu Sheikh Mujib Medical University (BSMMU) which maintained by the departments of Internal Medicine along with the physicians of all departments
The In-depth interview was conducted among 30 key prescribers of the different departments involve in the management of hospitalized COVID-19 patients and 285 COVID -19 positive patients who were admitted in BSMMU and among them 150 patient’s data were collected from record room and 135 patient’s data collected from the ward
60.9% (30/36) of the key prescribers of BSMMU hospital are aware of treatment guidelines
Summary
The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in Wuhan, China, in December 2019. The guidance emphasizes the role of supportive care based on severity of illness, ranging from symptomatic treatment for mild disease to evidence-based ventilator management for ARDS and early recognition and treatment of bacterial infections and sepsis in critically ill patients. In this regard, the WHO recently announced treatments plan to launch a global “megatrial’ (remdesivir, chloroquine or hydroxychloroquine, lopinavir/ritonavir, or lopinavir/ritonavir plus interferon-β) based on local drug availability.[4]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Bangabandhu Sheikh Mujib Medical University Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
